Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2019-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Certification Report) and includes detailed information about the internal control evaluation of Beijing SL Pharmaceutical Co., Ltd. for the year ended December 31, 2018. It is issued by a certified public accounting firm and contains an auditor's opinion on the effectiveness of internal controls related to financial reporting. The document includes detailed descriptions of the company's internal control environment, risk assessment, control activities, information and communication, and internal supervision. It also discusses the standards for identifying internal control deficiencies and the company's compliance with these standards. This type of document is a standalone audit-related report focusing on internal control over financial reporting, which fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. The document length (13,295 characters) and content confirm it is the report itself, not just an announcement or certification letter. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-04-23 Chinese
第七届监事会第五次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the seventh Supervisory Board of Beijing SL Pharmaceutical Co., Ltd. It includes voting results on various reports and proposals such as the 2018 Supervisory Board Work Report, 2018 Financial Final Report, 2018 Profit Distribution Plan, 2018 Annual Report and Summary, 2019 Q1 Report, 2018 Internal Control Evaluation Report, and the proposal to reappoint the audit firm for 2019. The document also mentions that these reports will be submitted to the 2018 Annual General Meeting for approval. The document is relatively short (2303 characters) and primarily serves as an announcement of meeting resolutions and voting outcomes rather than the full reports themselves. It does not contain detailed financial statements or substantive financial data but references that the full reports are available on the designated disclosure website. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially announces the voting results of the Supervisory Board meeting and the resolutions to be submitted to the shareholders' meeting.
2019-04-23 Chinese
内部控制规则落实自查表
Audit Report / Information Classification · 90% confidence The document is titled as an internal control self-assessment checklist from Beijing Shuanglu Pharmaceutical Co., Ltd. It details the company's internal audit, information disclosure, insider trading controls, fundraising controls, related party transactions, guarantees, major investments, and other important matters. The content is focused on internal control procedures and compliance rather than financial results or audit opinions. There is no indication that this is a full annual report, audit report, earnings release, or any other financial statement. The document is not a brief announcement or a certification letter but a detailed internal control report. Given the focus on internal control rules and audit committee operations, this fits best under Audit Report / Information (AR), which includes internal audit reports and applied accounting principles but excludes full annual reports. FY 2018
2019-04-23 Chinese
监事会对公司2018年内部控制评价报告的意见
Audit Report / Information Classification · 95% confidence The document is an opinion from the Supervisory Board regarding the company's 2018 internal control evaluation report. It references compliance with regulatory guidelines and internal control standards, and it provides an assessment of the internal control system's effectiveness. The document does not contain full financial statements or detailed financial data, nor is it an announcement of a report publication. It is a standalone audit-related opinion on internal controls, which fits the category of Audit Report / Information (AR). The document length is short but contains substantive content related to internal control evaluation, not just a notice or certification. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-04-23 Chinese
关于使用自有资金进行短期风险投资事项的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Beijing SL Pharmaceutical Co., Ltd. regarding the company's decision to use its own funds for short-term risk investment. It details the investment purpose, amount, objects, internal control measures, risk control, and opinions from independent directors and the supervisory board. The document is an announcement of a corporate financing/investment activity rather than a financial report or earnings release. It does not contain financial statements or detailed financial results but rather describes a capital usage decision and related governance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3225 characters, which is consistent with an announcement rather than a full report.
2019-04-23 Chinese
2019年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2019 年第一季度报告正文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2019 First Quarter Report." It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, asset and equity figures, and non-recurring gains and losses for the first quarter of 2019. The document also includes shareholder information and explanations of financial changes during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (6102 characters) and content confirm it is the full report, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2019
2019-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.